Engagement Of Cd43 Enhances Human Immunodeficiency Virus

Transcript

THE JOURNAL OF BIOLOGICAL CHEMISTRY © 2002 by The American Society for Biochemistry and Molecular Biology, Inc. Vol. 277, No. 32, Issue of August 9, pp. 28714 –28724, 2002 Printed in U.S.A. Engagement of CD43 Enhances Human Immunodeficiency Virus Type 1 Transcriptional Activity and Virus Production That Is Induced upon TCR/CD3 Stimulation* Received for publication, December 14, 2001, and in revised form, May 30, 2002 Published, JBC Papers in Press, June 3, 2002, DOI 10.1074/jbc.M111935200 Corinne Barat and Michel J. Tremblay‡§ From the ‡Centre de Recherche en Infectiologie, Hoˆpital CHUL, Centre Hospitalier Universitaire de Que´bec, and De´partement de Biologie Me´dicale, Faculte´ de Me´decine, Universite´ Laval, Ste-Foy, Que´bec G1V 4G2, Canada Human immunodeficiency virus type 1 (HIV-1) transcriptional activity is regulated by several cytokines and T cell activators. CD43 (sialophorin) is a sialoglycoprotein expressed on the surface of a wide variety of blood cells including T lymphocytes. Several studies have shown that CD43 ligation induces proliferation and activation of human T lymphocytes. We were thus interested in defining whether CD43-mediated signaling events can modulate the life cycle of HIV-1. We demonstrate here that CD43 cross-linking potentiates HIV-1 promoter-driven activity and virus production that is seen following the engagement of the T-cell receptor (TCR)䡠CD3 complex. This effect is independent of the CD28 co-stimulatory molecule and is mediated by both NF-␬B and NFAT transcription factors. A number of signal transducers known to be involved in the TCR/CD3dependent signal transduction pathway, including p56lck, p36lat, and SLP-76, as well as capacitative entry of calcium, are crucial for the noticed CD43 co-stimulatory effect. Calcium mobilization studies indicate that a synergy is occurring between CD43- and TCR/CD3-mediated signaling events leading to an augmented calcium release. These data suggest that CD43 can be seen as a co-stimulatory cell surface constituent that can modulate HIV-1 expression in T lymphocytes. Replication of human immunodeficiency virus type-1 (HIV1)1 is regulated by several cytokines and T cell activators via transcriptional regulation through the long terminal repeat (LTR) promoter and enhancer sequences. The nuclear factor ␬-B (NF-␬B) is playing a cardinal role in virus transcription via * This work was supported in part by Canadian Institutes of Health Research HIV/AIDS Program Grant HOP-15575 (to M. J. T.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. § Recipient of a Tier 1 Canada Research Chair in Human ImmunoRetrovirology. To whom correspondence should be addressed: Laboratoire d’Immuno-Re´trovirologie Humaine, Centre de Recherche en Infectiologie, RC709, Hoˆpital CHUL, Centre Hospitalier Universitaire de Que´bec, 2705 boul. Laurier, Ste-Foy, Que´bec G1V 4G2, Canada. Tel.: 418-654-2705; Fax: 418-654-2212; E-mail: Michel.J.Tremblay@ crchul.ulaval.ca. 1 The abbreviations used are: HIV-1, human immunodeficiency virus type 1; LTR, long terminal repeat; LAT, linker for activation of T-cells; NF-␬B, nuclear factor of ␬ chain in B cells; NFAT, nuclear factor for activated T-cells; SLP-76, SH2 domain-containing the leukocyte protein of 76 kDa; ZAP-70, ␨-chain-associated protein of 70 kDa; TCR, T-cell receptor; IL-2, interleukin 2; PBMC, peripheral blood mononuclear cell; VSV-G, vesicular stomatitis virus envelope glycoprotein G; CMV, cytomegalovirus; BAPTA, 1,2-bis(O-aminophenoxy)ethane-N,N,N⬘,N⬘-tetraacetic acid. the two tandem conserved NF-␬B-binding motifs that are located within the enhancer sequence (1). More recently, the implication of the NFAT family of transcription factors in HIV-1 LTR activity has been suggested (2), although contradictory results are still questioning the role of the different NFAT members. The regulatory domain of HIV-1 can be activated in vivo following engagement of the antigen-specific TCR䡠CD3 complex, an event that can be mimicked in vitro in established T-cell lines using some specific anti-CD3 monoclonal antibodies. It has been shown that antibody-mediated signaling through the TCR䡠CD3 complex activates HIV-1 transcription and co-engagement of CD28 further augmented virus gene expression (3, 4). Interestingly, ligation of CD28 alone is sufficient to induce HIV-1 transcription and replication both in Jurkat cells (5) and in naturally infected leukocytes (6). Considering the complex interplay between T-cell signaling events and HIV-1 replication, it is of prime importance to identify other cell surface constituents that are likely to affect HIV-1 transcription. An increasing number of accessory cell surface molecules are involved in up-regulation of T-cell activation. Among them, CD43 (sialophorin, leukosialin, or gpL115) is a constitutively phosphorylated 115-kDa sialoglycoprotein expressed in a wide variety of blood cells including lymphocytes, monocytes, neutrophils, and platelets. It is considered as the most abundant membrane protein of T lymphocytes. On Tcells, CD43 is differently glycosylated in two major isoforms, i.e. a 113–123-kDa product, mainly present on resting CD4⫹ T cells, and a 125–135-kDa form expressed mostly on resting CD8 lymphocytes. Previous work has shown that this isoform is up-regulated following activation of both CD4-positive and CD8-positive T-cells (7). CD43 has been involved in the selection and maturation of thymocytes and in the migration, adhesion, and activation of mature T-cells. Four natural ligands have been identified for CD43, namely ICAM-1 (CD54), Galectin 1, major histocompatibility complex-I, and sialoadhesin (Siglec-1). However, there is no direct evidence of how the interaction of CD43 with these ligands regulates T-cell function (8 –11). Numerous reports document a role for CD43 in T-cell signaling. For example, CD43 ligation by monoclonal antibodies has been reported to increase proliferation of activated T-cells and to enhance antigen-specific activation of T-cells, resulting in secretion of IL-2 and expression of both CD69 and CD40L (12–15). Such CD43-mediated effects are independent from the CD28 receptor (16, 17) and require the intracellular domain of CD43, which is hyperphosphorylated during T-cell activation. Further studies revealed that CD43 is functionally coupled to the phospholipase C/phosphoinositides signaling pathway, resulting in translocation of protein kinase C to the membrane 28714 This paper is available on line at http://www.jbc.org TCR/CD43 Co-stimulation of HIV-1 LTR and calcium mobilization (18, 19). The mitogen-activated protein kinase pathway has been demonstrated to be involved in CD43-dependent interleukin-2 gene expression (20). Also, CD43 cross-linking on the T-cell surface induces interaction between CD43 and Fyn leading to Fyn tyrosine phosphorylation and signal propagation (21). Downstream events of the CD43-mediated signaling cascade include activation of several transcription factors such as activator protein-1, NFAT, and NF-␬B (22). Besides its co-stimulatory potential, a negative regulatory role in T-cell activation was proposed for CD43 based on the observation that CD43-deficient mice are hyperresponsive following both in vivo and in vitro activation (23). However, in another study, the absence of CD43 did not alter T-cell development and responsiveness (24). CD43 has been shown to induce apoptosis in human T-cell lineages (25) and, paradoxically, a high level of CD43 expression can protect T-cell hybridomas from activation-induced cell death (26). Further studies are thus warranted to document the exact contribution of CD43 in T-cell functions. More relevant to the present work, persons infected with HIV-1 make autoantibodies that bind to CD43 on normal thymic lymphocytes (27). Moreover, an altered glycosylation pattern of CD43 is observed on the surface of HIV-1-infected CEM cells and also on peripheral T lymphocytes from patients infected with HIV-1 (28, 29). These findings along with the previously reported implication of CD43 in T-cell signaling and the intimate link between T-cell activation and HIV-1 transcription (30) led us to scrutinize the effect of CD43 ligation on the regulatory elements of HIV-1. In the present study, we provide evidence indicating that, although CD43-mediated signal transduction events are weak inducers of virus transcription, co-ligation of CD43 with the TCR䡠CD3 complex markedly augmented both HIV-1 LTR-driven gene activity and virus gene expression. This CD43-dependent co-stimulus was independent of CD28 and promoted nuclear translocation of both NF-␬B and NFAT transcription factors. Several intracellular second messengers known to participate to the TCR/CD3 signaling cascade were found to be important for the CD43 co-stimulating ability, therefore suggesting that stimulation via CD43 could act by lowering the threshold for T-cell activation that is seen upon the engagement of the TCR䡠CD3 complex. EXPERIMENTAL PROCEDURES Cells Used in This Study—The cell lines used in this work include parental Jurkat (clone E6.1), 1G5, JCAM1.6, JCAM.2, J14-V-29, J1476-11, CJ, CJ 5.13, CJ 1.1, and LuSIV. Jurkat is considered as a model cell line for the study of T-cell signaling machinery (31), whereas the 1G5 T-cell line is a Jurkat derivative that harbors two stably integrated constructs constituted of the luciferase gene under the control of the HIV-1 SF2 LTR (32). JCAM1.6 and JCAM2 are Jurkat derivatives that are deficient in p56lck and p36lat expression, respectively (33, 34). The J14-V-29 cell line is also derived from Jurkat and lacks expression of the T cell specific adaptor SLP-76 that has been reintroduced using an expression vector, thus creating the J14-76-11 clone (35). The CJ cell lines have been derived from Jurkat using a toxic gene under the control of the NFAT transcription factor (36). The CJ parental cell line retains full calcium capacitative entry, whereas the CJ 5.13 and CJ 1.1 have, respectively, 40 and less than 10% of the wild-type capacitative entry of calcium following stimulation. The reporter LuSIV cell line, kindly provided by Janice E. Clements (Johns Hopkins University School of Medicine, Baltimore, MD), was derived from the CEMx174 parental cell line (B-cell/T-cell hybrid) and carries the luciferase reporter gene under the control of the SIVmac239 LTR (37). All cell lines were grown in RPMI containing 10% fetal calf serum (Hyclone Laboratories) and supplemented with penicillin and streptomycin except for CJ cell lines, which were grown in 20% fetal calf serum. Peripheral blood mononuclear cells (PBMCs) were obtained from healthy donors and purified by Ficoll-Hypaque centrifugation. PBMCs were maintained in RPMI medium (described above) containing 1 ␮g/ml PHA-L and 50 units/ml IL-2 for 1 week. PBMCs were deprived from IL-2 for 24 h before being used in stimulation assays. Human T helper cells (i.e. 28715 CD4⫹) were negatively isolated from fresh PBMCs using the CD4⫹ T cells negative purification kit according to the manufacturer’s instructions (Miltenyi Biotec). Briefly, we have used an antibody mixture and a magnetic colloid that depletes the cell population of every cell type except CD4⫹ T lymphocytes upon application to a magnetically charged column. Vectors and Antibodies—In our studies we have used pLTR-LUC and pm␬BLTR-LUC that have been kindly provided by Dr. K. Calame (Columbia University, New York). These molecular constructs contain the luciferase reporter gene under the control of wild-type (GGGACTTTCC) or NF-␬B-mutated (CTCACTTTCC) HIV-1HXB2 LTR (⫺453 to ⫹80) (38). The pLTRX-LUC plasmid contains a 722-base pair fragment (⫺644 to ⫹78) from HIV-1LAI placed in front of the luciferase reporter gene (39) and was kindly given by Dr. O. Schwartz (Unite´ d’oncologie virale, Institut Pasteur, France). The p␬B-TATA-LUC vector contains the minimal HIV-1 ␬B region and a TATA box placed upstream of the luciferase reporter gene (40) (from Dr. W. C. Greene, The J. Gladstone Institutes, San Francisco, CA). The following reagents were obtained through the National Institutes of Health AIDS repository reagent program: pNL4-3, a full-length infectious molecular clone of HIV-1 (a prototypic T-tropic isolate of HIV-1) (41), and pCEP4-Tat, a plasmid that contains the HIV-1SF2 Tat gene ligated to the pCEP4 CMV-based expression vector (42). The dominant negative I␬B␣ expressing vector pCMV-I␬B␣ S32A/S36A has been described previously (40). pNFATLUC is constituted of the luciferase reporter gene placed under control of the minimal IL-2 promoter that carries three tandem copies of the NFAT-binding site (kindly provided by Dr. G. Crabtree, Howard Hughes Medical Institute, Stanford, CA) (43). pNF␬B-LUC contains five consensus NF-␬B binding sequences placed upstream of the luciferase gene along with a minimal promoter (Stratagene). The expression vector for p56lck, pEFneo LCK-wt, as well as the pEFneo-based empty vector have already been described (44) and were kind gifts from Dr. C. Couture (Lady Davis Institute, Montreal). The expression vector for p36LAT, pCDNA3.1 LAT, was generously provided by Dr. A. Weiss (University of California, San Francisco, CA) (34). The luciferase-containing pNL4-3-LUC-E-R⫹ construct was generously provided by Dr. N. R. Landau (The Salk Institute for Biological Studies, La Jolla, CA). The pHCMV-G expressing the broad host-range vesicular stomatitis virus envelope glycoprotein G (VSV-G) from the human cytomegalovirus promoter has been described previously (45). The hybridoma cell line that produces the anti-CD3 OKT3 monoclonal antibody (specific for the ␨-chain of the CD3 complex) was obtained from the American Type Culture Collection (Manassas, VA). Purified anti-CD28 antibody (clone 9.3) was a generous gift from Dr. J. A. Ledbetter (Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, NJ) (46). Two anti-CD43 antibodies reacting with different epitopes were used in this study: L10, which reacts with both sialylated and desialylated CD43 (15), was purchased from Caltag (Burlingame, CA), whereas MEM-59, which is directed against a sialic acid-dependent epitope (47), is a kind gift from Dr. V. Horejski (University of Prague, Czech Republic). Purified goat anti-mouse IgG antibody was obtained from Jackson ImmunoResearch (West Grove, PA). Rabbit antisera raised against peptides from NFAT1 (48) or the p50 and p65 subunits of NF-␬B were kindly supplied by Dr. N. Rice (NCI-Frederick, National Institutes of Health, Frederick, MD). Polyclonal anti-NFATc (NFAT2) antibody was obtained from Santa Cruz Biotechnology (Santa Cruz, CA). Transient Transfection and Cell Stimulation—Cells were electroporated at room temperature using a gene pulser I apparatus (Bio-Rad) (960 microfarads, 250 V). Cells were concentrated at 37.5 ⫻ 106/ml in RPMI medium. Cells (400-␮l aliquots) were electroporated either with 5 ␮g of the reporter construct DNA alone or, in the case of reconstitution experiments, with 5 ␮g of reporter construct DNA and 0, 10, or 20 ␮g of the expression plasmid. The total DNA amount for the reconstitution experiments was maintained constant at 25 ␮g using the empty vector. To minimize variations in plasmid transfection efficiencies, cells were transfected in bulk and were separated into various treatment groups at a density of 105 cells/well (100 ␮l) in 96-well flat-bottom plates at 36 h post-transfection. For studies using the pharmacological inhibitor FK506 (Sigma), cells were resuspended in fresh cell culture medium at 1 ⫻ 106 cells/ml, and FK506 was added at subcytotoxic concentrations of 1–10 ng/ml for 60 min before stimulation. Cells were either left unstimulated or treated with various combinations of anti-CD3 (clone OKT3, 0.25 ␮g/ml unless otherwise specified), anti-CD43 (MEM-59 at 3 ␮g/ml or L10 at 1 ␮g/ml), and anti-CD28 antibody (clone 9.3 at 1 ␮g/ml), and cross-linked with a goat anti-mouse IgG (2 ␮g/ml) in a final volume of 200 ␮l. Next, cells were incubated at 37 °C for 8 h unless otherwise specified. Luciferase activity was determined following a previously described protocol (49). 28716 TCR/CD43 Co-stimulation of HIV-1 LTR Production of Virus Stocks and Virus Infection—Virus particles were produced by calcium phosphate transfection of 293T cells with virusencoding vectors as previously described (50, 51). Pseudotyped HIV-1 particles were generated by cotransfection of 293T cells with pNL4-3LUC-E-R⫹ and an expression vector coding for the VSV-G full-length envelope protein. Virus stocks were normalized for virion content using an in-house sensitive double antibody sandwich enzyme-linked immunosorbent assay specific for the major core viral p24 protein (52). Viral infection experiments were done using fixed amount of virus (5 ng of p24 protein) to inoculate 105 target cells (i.e. Jurkat, PBMCs, and purified CD4⫹ T lymphocytes). Cells infected with luciferase-encoding viruses were stimulated 48 h post-infection as described above and luciferase activity was monitored at 24 h post-stimulation. Cells infected with replication-competent viruses (i.e. NL4-3) were stimulated 8 h post-infection. Production of infectious viruses by NL4-3-infected CD4⫹ T lymphocytes at 3 days post-stimulation was assessed using the reporter LuSIV cell line. Briefly, cell-free culture supernatants were incubated with LuSIV cells (105), and luciferase activity was analyzed at 24 h after the initiation of the culture. Preparation of Nuclear Extracts and Electrophoretic Mobility Shift Assay—Nuclear extracts were prepared according to a previously described protocol (49). Briefly, unstimulated or activated cells (5 ⫻ 106) were first washed with phosphate-buffered saline. Cells were then resuspended in 400 ␮l of hypotonic buffer (Buffer A: 10 mM HEPES, pH 7.9, 10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, 1 mM dithiothreitol, 0.5 mM phenylmethylsulfonyl fluoride) and kept for 15 min on ice before lysis with 25 ␮l of 10% Nonidet P-40. After brief vortexing and centrifugation, the supernatant was discarded, and the pellet was resuspended with an hypertonic buffer (Buffer B: 20 mM HEPES, pH 7.9, 0.4 M NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM dithiothreitol, 1 mM phenylmethylsulfonyl fluoride) followed by gentle agitation for 15 min. The solution was then centrifuged and the supernatant was assayed for protein concentration by BCA assay (Pierce) and stored at ⫺85 °C until use. Nuclear extracts (10 ␮g) were incubated for 20 min at room temperature in 20 ␮l of 1⫻ binding buffer (100 mM HEPES, pH 7.9, 40% glycerol, 10% Ficoll, 250 mM KCl, 10 mM dithiothreitol, 5 mM EDTA, 250 mM NaCl, 2 ␮g of poly(dI-dC), and 10 ␮g of nuclease-free bovine serum albumin fraction V) containing 0.8 ng of ␥-32P-labeled double-stranded DNA oligonucleotide. The following double-stranded DNA oligonucleotides were used as probes and/or competitors: the enhancer region (-107/-77) from the NL4-3 strain of HIV-1 (5⬘-CAAGGGACTTTCCGCTGGGGACTTTCCAGGG-3⬘), and the consensus binding site for Oct-2A (used as a control for nonspecific competition). Oligonucleotides were synthesized in-house. DNA-protein complexes were resolved from free labeled DNA by electrophoresis in native 4% (w/v) polyacrylamide gels. The gels were subsequently dried and autoradiographed on a KodakTM Biomax MR film at ⫺85 °C. Cold competition assays were conducted by adding a 100-fold molar excess of unlabeled double-stranded DNA oligonucleotide simultaneously with the labeled probe. Supershift assays were performed by preincubation of nuclear extracts with 1 ␮l of antibody in the presence of all of the components of the binding reaction for 30 min on ice before the addition of the labeled probe. Flow Cytometric Analysis of Intracellular Calcium—Cells (1 ⫻ 107) were washed once and resuspended in RPMI 1640 supplemented with 10% fetal calf serum at a concentration of 1 ⫻ 107 cells/ml. The cell permeant calcium indicator Indo-1AM (Molecular Probes, Eugene, OR) was added to the cells at a final concentration of 3 ␮M and the cells were incubated in the dark at room temperature for 1 h with moderate shaking. Cells were then washed twice with ice-cold serum-free/phenol red-free Opti-MEM medium (Invitrogen) and resuspended in OptiMEM at a concentration of 1 ⫻ 106 cells/ml. Thereafter, prewarmed cells (1 ⫻ 106) were stimulated with various combinations of anti-CD3 (clone OKT3) and anti-CD43 (MEM-59 or L10) along with a goat antimouse IgG (2 ␮g/ml) and the calcium content was then analyzed with an EPICS ELITE ESP apparatus (Beckman-Coulter, Miami, FL). The violet:blue ratios, representing the Ca2⫹-bound to Ca2⫹-unbound Indo-1 signals, were then continuously monitored over a 10-min period and analyzed using the 1.5 version of the System 2 software (BectonCoulter). Data are presented as the geometric mean of the violet:blue ratio over time, using WinMDI version 2.8 freeware (J. Trotter, The Scripps Institute, La Jolla, CA). RESULTS TCR/CD3-mediated Induction of HIV-1 LTR Activity Is Increased upon CD43 Ligation, Both in the Absence or Presence of the Viral Tat Protein—Because the engagement of CD43 has been shown to enhance T-cell activation and induce IL-2 gene expression, we were interested in analyzing the effects of CD43-mediated signals on HIV-1 LTR-driven transcriptional activity. To this end, we used two anti-CD43 antibodies reacting with different epitopes, i.e. MEM-59 and L10. 1G5 cells, a Jurkat-derived cell line that contains a stably integrated construct made of the luciferase reporter gene under the control of the HIV-1LAI LTR, were incubated with anti-CD43 antibodies used either alone or in combination with anti-CD3 antibodies. As shown in Fig. 1A, no increase in luciferase activity was observed upon treatment with anti-CD43 antibodies alone. However, both MEM-59 and L10 showed a co-stimulating effect when used in combination with the anti-CD3 antibody OKT3. The up-regulating effect was even more dramatic when using p␬BTATA-LUC, a molecular construct made of the luciferase reporter gene placed under the control of the minimal HIV-1 promoter region (Fig. 1B). This could be attributed to the deletion of the HIV-1 LTR negative regulatory elements in this construct. In both cases the L10 antibody showed much stronger co-stimulating activity as compared with MEM-59. Data from a time course experiment revealed that the optimal costimulating capacity of CD43 was maximal after 8 h of treatment (Fig. 1C). Interestingly, a significant induction of HIV-1 LTR-dependent luciferase activity was seen (30-fold increase over untreated cells) even with concentrations of OKT3 that were not sufficient to mediate activation by itself (i.e. from 0.05 to 0.2 ␮g/ml) (Fig. 1D). Moreover, the marked co-stimulating potential of the L10 antibody was not affected by a reduction in the concentration of OKT3 to as low as 0.05 ␮g/ml and was still observed at 0.025 ␮g/ml. In contrast, the co-stimulating potential of the MEM-59 antibody appears to be more dependent on the anti-CD3 concentration, suggesting that these two antibodies could act via different mechanisms. Our next set of experiments was performed using pLTRXLUC, a vector that carries the reporter luciferase gene placed under the control of the complete HIV-1LAI LTR region. As shown in Fig. 2A, the tested anti-CD43 antibodies (i.e. MEM-59 and L10) led to a significant increase in LTR activity when used in combination with a suboptimal dose of OKT3. Because the virus-encoded transactivating Tat protein is crucial for virus replication both in vivo and in vitro, we next wanted to assess the implication of Tat protein on the CD43-mediated co-stimulating capacity. To this end, Jurkat cells were co-transfected with pLTRX-LUC along with a Tat expression vector (i.e. pCEP4-Tat). Data from Fig. 2B indicate that even when the LTR-driven expression is increased more than 100-fold by Tat, ligation of CD43 can still provide a co-stimulatory signal to a suboptimal TCR/CD3 triggering. Previous findings have indicated that CD28 provides a costimulating potential with respect to HIV-1 replication and transcription (3). In agreement with such findings, an additive effect was noticed when a monoclonal anti-CD28 antibody (i.e. clone 9.3) was used along with L10, leading to a 100-fold increase in luciferase activity (Fig. 3). Because we have used a saturating concentration of anti-CD28 antibody to perform these studies (i.e. 1 ␮g/ml), this observation suggests that the CD43 co-stimulating potential is independent from CD28, and most likely uses a distinct signaling pathway. NF␬B and NFAT Are Involved in CD43-mediated Cooperative Effect on HIV-1 Transcription—Regulation of HIV-1 transcription that is seen with several stimuli, including CD3 and CD28 ligation, involves the NF-␬B complex via the two tandem conserved motifs located in the enhancer region (1). To test the involvement of the ubiquitous mammalian transcription factor NF-␬B in the co-stimulating activity of CD43, Jurkat cells were transfected with reporter constructs harboring either the full- TCR/CD43 Co-stimulation of HIV-1 LTR 28717 FIG. 1. CD43 provides a co-signal that enhances TCR/CD3-mediated induction of HIV-1 LTR activity. 1G5 cells (A) or Jurkat cells transiently transfected with p␬BTATA-LUC (B) were either left untreated or incubated with OKT3 (1 ␮g/ml), MEM-59 (3 ␮g/ml), L10 (1 ␮g/ml), OKT3 and MEM-59, or OKT3 and L10 for 8 h before monitoring LTR-driven luciferase activity. C, Jurkat cells were transiently transfected with p␬BTATA-LUC and were next stimulated for the indicated times with OKT3 (0.25 ␮g/ml) (f), L10 (1 ␮g/ml) (●), or OKT3 and L10 (Œ). D, Jurkat cells were first transiently transfected with p␬BTATA-LUC and were next stimulated for 8 h with various concentrations of OKT3 either used alone (filled bars) or in combination with MEM-59 (gray bars) or L10 (stripped bars). Results are presented as -fold induction in luciferase activity over untreated samples from the calculated mean ⫾ S.D. of four different lysed cell samples in the same experimental setting. These results are representative of three different experiments. length LTR promoter (i.e. pLTR-LUC) or a LTR bearing mutated NF-␬B-binding sites (i.e. pm␬BLTR-LUC) in the presence of various combinations of anti-CD3 and anti-CD43 antibodies. As shown in Fig. 4A, the increase in HIV-1 LTR activity mediated by co-ligation of the TCR䡠CD3 complex and CD43 was significantly reduced but not totally inhibited in cells transfected with the NF-␬B-mutated molecular construct. Previous findings have indicated that nuclear translocation and activation of NF-␬B is mainly mediated by the degradation of the repressor I␬B␣, which sequester the complex in the cytoplasm (54). To confirm the implication of NF-␬B in the observed co-stimulating effect of CD43, we used a dominant negative version of I␬B␣ mutated on serines 32 and 36, which is unable to be serine phosphorylated, and hence, degraded. When the pCMV-I␬B␣ S32A/S36A vector was transfected along with the reporter plasmid p␬BTATA-LUC, the TCR/CD3- and CD43-dependent induction of virus transcription was severely reduced but again not completely abolished by this expression vector (Fig. 4B). Finally, we used a construct containing five consensus NF-␬B binding sequences placed upstream from the luciferase gene along with a minimal promoter (i.e. pNF␬B-LUC). As depicted in Fig. 4C, activation of NF-␬B was indeed enhanced following co-engagement of the TCR䡠CD3 complex with CD43. Although NF-␬B is considered as a key regulator in HIV-1 expression, the NFAT family of transcription factors has also been shown to participate in virus gene expression (2, 55, 56). Given that mutations in the NF-␬B-binding sites in the LTR region and the use of a trans-dominant repressor of I␬B␣ do not completely abrogate the co-stimulatory activity of CD43 (Fig. 4, 28718 TCR/CD43 Co-stimulation of HIV-1 LTR FIG. 2. CD43-mediated co-stimulation is observed in the absence or presence of the viral Tat protein. Jurkat cells were transiently transfected with pLTRX-LUC (A) or co-transfected with pLTRX-LUC and a Tat-coding vector (B). Next, cells were either left untreated or treated for 8 h with OKT3 (0.25 ␮g/ml), MEM-59 (3 ␮g/ml), OKT3 and MEM-59, L10 (1 ␮g/ml), or OKT3 and L10. Results are presented in luciferase activity from the calculated mean ⫾ S.D. of four different lysed cell samples in the same experimental setting. These results are representative of three different experiments. -Fold increase over untreated cells is indicated at the top of some bars. NT, not treated. FIG. 3. CD43-dependent co-stimulating activity is distinct from CD28. Jurkat cells were transiently transfected with p␬BTATALUC and were next either left untreated or treated for 8 h with OKT3 (0.25 ␮g/ml) alone or in combination with an anti-CD28 antibody (9.3 at 1 ␮g/ml), L10 (1 ␮g/ml), or both antibodies. Results are presented as -fold induction in luciferase activity over untreated samples from the calculated mean ⫾ S.D. of four different lysed cell samples in the same experimental setting. These results are representative of three different experiments. A and B), NFAT could also play a role in the CD43-dependent signaling events. To test this hypothesis, we used the immunosuppressor FK506, which has been shown to block NFAT activation through the inhibition of calcineurin activity (57, 58). 1G5 cells were first pretreated with FK506 for 60 min and next stimulated with anti-CD3 and anti-CD43 antibodies. Data from Fig. 5A indicate that treatment with FK506 caused a 2-fold decrease of HIV-1 transcriptional activity that was the result of TCR/CD3 and CD43 co-engagement, therefore sug- gesting an implication of a calcineurin-dependent signal transducer such as NFAT. Similar results were obtained when using Jurkat cells transiently transfected with p␬BTATA-LUC where 1 and 10 ng/ml FK506 caused a 2- and 3-fold diminution of luciferase activity, respectively (Fig. 5B). Considering that the HIV-1 enhancer sequence present in the p␬BTATA-LUC vector bears only NF-␬B- and NFAT-binding sites, these results strongly suggest the involvement of NFAT in HIV-1 LTR stimulation induced by TCR/CD3-CD43 co-ligation. To confirm this hypothesis, Jurkat E6.1 cells were transfected with pNFATLUC, a construct containing three NFAT-binding sites upstream from the minimal IL-2 promoter. Co-ligation of the TCR䡠CD3 complex and CD43 resulted in a 7-fold increase in luciferase activity, whereas only a 1.3-fold increase was observed following cross-linking of the TCR䡠CD3 complex alone (Fig. 5C). These results indicate that co-stimulation via CD43 acts not only via the NF-␬B complex, but also via members of the NFAT family. CD43-mediated Signal Transduction Cooperates with TCR/ CD3 to Increase Nuclear Translocation of NF-␬B and NFAT in Human T Lymphoid and Primary Cells—We were next interested in defining whether the CD43-mediated signaling pathway could either alone or in conjunction with TCR/CD3 stimulation modulate the level of HIV-1 enhancer-bound protein complexes. To this end, electrophoretic mobility shift assay experiments were conducted with a labeled probe containing the complete enhancer region of the HIV-1 LTR (⫺107/⫺77). Incubation of the HIV-1 enhancer probe with nuclear extracts from anti-CD3- or anti-CD43-treated Jurkat cells led to the formation of a single broad signal, which was much stronger upon co-ligation of TCR/CD3 and CD43 (Fig. 6A, compare lanes 2–6). It has already been shown that this signal can be the result of an overlapping of NF-␬B and NFAT complexes (59). To discriminate the NFAT-related band from the NF-␬B complex, supershift assays were performed using extracts from OKT3and OKT3/L10-stimulated cells that were incubated with antiNF-␬B p50 and anti-NFAT1 antibodies (Fig. 6A, lanes 7–12). The upper part of the migrating complex was identified as the TCR/CD43 Co-stimulation of HIV-1 LTR FIG. 4. Co-stimulatory effect of CD43 on HIV-1 LTR activity is mediated by NF-␬B. A, Jurkat cells were transiently transfected with wild-type- or NF-␬B-mutated HIV-1 LTR-driven luciferase vectors before stimulation for 8 h with the indicated antibodies. B, Jurkat cells were co-transfected with p␬BTATA-LUC and either an empty control vector or a CMV-based plasmid coding for a dominant negative form of I␬B␣. Next, cells were treated for 8 h with the listed antibodies. C, Jurkat cells were transfected with pNF␬B-LUC before incubation for 8 h with the indicated antibodies. Finally, cells were lysed, and luciferase activity was assessed as described under “Experimental Procedures.” Results are presented as -fold induction in luciferase activity over untreated samples from the calculated mean ⫾ S.D. of four different lysed cell samples in the same experimental setting. These results are representative of three different experiments. NFAT complex, whereas the NF-␬B complex was responsible for the lower part. The signal intensity of both complexes was increased following engagement of both CD43 and the TCR䡠CD3 complex (compare lanes 7–9 with 10 –12). Electrophoretic mobility shift assays were also performed with nuclear extracts from IL-2-starved human PBMCs. As shown in Fig. 6B, similar findings were made in such cells, except that the NFAT1-specific complex was very faint and could be seen only when the NF-␬B complex was supershifted (lane 13). The specificity of the complexes was demonstrated by competition with a 100-fold excess of a specific or nonspecific oligonucleotide (lanes 7 and 8). Translocation of NFAT1 was also confirmed using an NFAT-specific labeled probe (data not shown). Altogether these results substantiate our observations indicating that co-ligation of CD43 and the TCR䡠CD3 complex 28719 FIG. 5. NFAT is also required for the CD43 co-stimulatory effect on HIV-1 transcription. A, 1G5 cells were pretreated for 60 min with FK506 (10 ng/ml) before treatment with OKT3 (1 ␮g/ml) used either alone or in combination with MEM-59 (3 ␮g/ml) and L10 (1 ␮g/ml). B, Jurkat cells were transiently transfected with the p␬BTATALUC molecular construct and were next pretreated for 60 min with FK506 (1 and 10 ng/ml) before treatment with OKT3 (0.25 ␮g/ml) that was used either alone or in combination with MEM-59 and L10. C, Jurkat cells were first transfected with pNFAT-LUC before incubation for 8 h with the indicated antibodies. Cells were finally lysed to monitor luciferase activity. Results are presented as -fold induction in luciferase activity over untreated samples from the calculated mean ⫾ S.D. of four different lysed cell samples in the same experimental setting. These results are representative of three different experiments. induces more important NF-␬B as well as NFAT-binding activities on the HIV-1 enhancer. The Src Family Protein-tyrosine Kinase p56lck, the Adapter Molecules p36lat and SLP-76, and Capacitative Entry of Calcium Are All Critical for HIV-1 LTR Activation by CD43-TCR/ CD3 Co-ligation—Although CD43 demonstrates a potent costimulating effect on TCR/CD3-dependent induction of HIV-1 LTR-driven reporter gene activity, signal transduction events mediated through CD43 are not sufficient per se to up-regulate virus transcription. This may suggest that the TCR/CD3-oriented signaling pathway was involved in transducing the TCR/ CD3-CD43 co-ligation signal. Previous work has reported that the TCR/CD3 signaling cascade was initiated by the Src family 28720 TCR/CD43 Co-stimulation of HIV-1 LTR FIG. 6. Co-ligation of CD43 and TCR/CD3 results in NF-␬B and NFAT binding activities onto the HIV-1 enhancer region. A, Jurkat cells were either left unstimulated (lane 1) or stimulated for 4 h with OKT3 (lanes 2 and 7–9), L10 (lane 3), OKT3 and L10 (lanes 4 and 10 –12), MEM-59 (lane 5), or OKT3 and MEM-59 (lane 6). Nuclear extracts were incubated with an HIV-1 enhancer-labeled probe, and the complexes were resolved on a native 4% polyacrylamide gel. Supershift assays were performed with an anti-NF-␬B p50 (lanes 8 and 11) or an anti-NFAT1 antibody (lanes 9 and 12). B, human PBMCs were either left unstimulated (lane 1) or stimulated for 4 h with OKT3 (lane 2 and 9 –11), L10 (lane 3), OKT3 and L10 (lanes 4 and 12–14), MEM-59 (lane 5), or OKT3 and MEM-59 (lane 6 – 8) before preparing nuclear extracts. Electrophoretic mobility shift assays were then carried out using an HIV-1 enhancer probe. Competitions were performed with a 100-fold excess of either specific (lane 7) or nonspecific (lane 8) oligonucleotides. Supershift assays were performed with an anti-NF-␬B p50 (lanes 10 and 13) or an anti-NFAT1 antibody (lanes 11 and 14). NFAT- and NF-␬B-specific complexes are indicated. Arrows on the right side indicate supershifted bands. protein-tyrosine kinase p56lck, which phosphorylates immunoreceptor tyrosine-based activation motifs of the CD3␨ chains (60). These phosphorylated motifs provide anchoring for the Syk family protein-tyrosine kinase ZAP-70 that becomes activated (61) and was then responsible for phosphorylation of downstream effectors such as p36LAT (62) and SLP-76 (63). To assess the implication of these effectors in the co-stimulating signal provided by CD43, we used cell lines that are deficient for p56lck (JCAM1.6), p36lat (JCAM2), or SLP-76 (J14-V29). When these cell lines were transfected with p␬BTATA-LUC, no increase in luciferase activity was observed upon stimulation with anti-CD3 and anti-CD43 antibodies (Fig. 7, panels A–C). This unresponsiveness was not related to a lack of CD43 molecule, because flow cytometric analyses revealed that these cell lines express surface levels of CD43 similar to the parental Jurkat cell line (data not shown). Reconstitution experiments performed with JCAM1.6 cells transfected with a p56lck-expression vector indicate that expression of p56lck partially restored induction of HIV-1 LTR activity following CD43 and TCR/CD3 co-engagement (Fig. 7A). The SLP-76-deficient cell line J14-V29 was also unresponsive to CD43 and TCR/CD3 stimulation, whereas the SLP-76-reconstituted J14-76-11 cells showed a partially restored response to this type of stimuli (Fig. 7C). Altogether these results demonstrate the importance of the most proximal TCR/CD3-mediated signaling events in the co-stimulating activity of CD43. More distal events following TCR/CD3 stimulation include phospholipase C␥1-dependent inositol triphosphate generation, an event leading to the release of calcium from intracellular stores. This initial burst of calcium is followed by an FIG. 7. The Src family protein-tyrosine kinase p56lck, the adapter molecules p36LAT and SLP-76, and capacitative entry of calcium are all important for CD43- and TCR/CD3-mediated enhancement of virus transcription. A, Lck-deficient JCAM1.6 cells were cotransfected with p␬BTATA-LUC and either an empty control vector (i.e. pEFneo) or a p56lck-encoding plasmid (i.e. pEFneop56lck) before treatment with the indicated antibodies. B, parental Jurkat and LAT-deficient JCAM2 cells were first transiently transfected with p␬BTATA-LUC and next incubated with the listed antibodies. C, SLP-76-defective J14-V29 and SLP-76-reconstituted J14-76-11 cells were transiently transfected with p␬BTATA-LUC and then stimulated with the indicated antibodies. D, Jurkat cells showing normal (CJ), intermediate (CJ 5.13), or very low (CJ 1.1) capacitative calcium entry were transiently transfected with p␬BTATA-LUC before treatment with OKT3 used either alone or in combination with the antiCD43 antibodies. Cells were lysed to measure luciferase activity after an incubation period of 8 h. Results are presented as -fold induction in luciferase activity over untreated samples from the calculated mean ⫾ S.D. of four different lysed cell samples in the same experimental setting. These results are representative of three different experiments. influx of extracellular calcium ions, also called capacitative calcium entry that is necessary for a sustained activation of calcium effectors and to replenish calcium stores (64). We analyzed the role of this signaling cascade in CD43 co-stimulation using Jurkat-derived cell lines demonstrating full (CJ), intermediate (CJ 5.13), or low (CJ 1.1) capacitative entry of calcium. These cell lines were first transfected with p␬BTATA-LUC before stimulation with anti-CD43 and anti-CD3 antibodies. Results from Fig. 7D demonstrate that the process of capacitative calcium entry represents a crucial event in the CD43 co-stimulating activity. The implication of calcium-related effectors was confirmed by showing that treatment with the intracellular calcium chelator BAPTA-AM or the inhibitor of internal calcium release TMB-8 resulted in inhibition of CD43mediated co-stimulating effect on HIV-1 LTR transcriptional activity (data not shown). To further assess the involvement of calcium-related events in this signal transduction pathway, we measured the extent of calcium mobilization following CD43 and/or TCR/CD3 ligation. Accurate measurements of intracellular calcium release can be achieved through the use of the Indo-1 dye by calculating the ratio of calcium-bound Indo-1 over calcium-free Indo-1. The addition of a suboptimal dose of anti-CD3 or anti-CD43 to Jurkat cells led to a slow but significant increase in intracellular calcium content. This increase was faster and much stronger when the anti-CD3 and the anti-CD43 antibody L10 were used in combination (Fig. 8). No such additive effect could be observed when the MEM-59 antibody was used in conjunction with anti-CD3. TCR/CD43 Co-stimulation of HIV-1 LTR 28721 FIG. 9. HIV-1 gene expression and virus production are increased following occupancy of both CD43 and TCR/CD3. Jurkat cells (A) or human PBMCs (B) were infected with VSV-G luciferaseencoding HIV-1 particles. Forty-height h post-infection, cells were stimulated for 24 h with the indicated antibodies before assessing virusencoded reporter gene activity. C, purified human T helper cells (CD4⫹) were initially infected with fully competent HIV-1NL4-3 particles, and were next stimulated 8 h post-infection with the indicated antibodies. Virus production was monitored at day 3 post-stimulation by incubating cell-free culture supernatants with indicator LuSIV cells. Results are presented in luciferase activity from the calculated mean ⫾ S.D. of four different lysed cell samples in the same experimental setting. These results are representative of three different experiments. -Fold increase over untreated cells is indicated at the top of some bars. NT, not treated. FIG. 8. Calcium mobilization is increased following engagement of both CD43 and TCR䡠CD3 complex. Jurkat cells were first loaded with Indo-1 AM before treatment with the indicated cross-linked antibodies. Calcium mobilization was monitored for 10 min. Data are represented as the geometric mean of the violet:blue ratio (y axis) over time (x axis). Arrows indicate the addition of the antibody. Co-ligation of CD43 and TCR/CD3 Results in an Augmentation of HIV-1 Transcription and Virus Production When using VSV-G Pseudotypes and Fully Infectious HIV-1 Particles—We next wanted to test the CD43-dependent enhancement of HIV-1 transcriptional activity in the context of a more complete viral genome. This goal was reached by infecting Jurkat cells with recombinant luciferase-encoding HIV-1 particles that were pseudotyped with the broad host-range VSV-G envelope protein. Treatment of such virally infected human T lymphoid cells with anti-CD43 and anti-CD3 antibodies resulted in a significant increase in virus-encoded reporter gene activity (Fig. 9A). Similar results were observed upon infection of human PBMCs with such VSV-G pseudotypes (Fig. 9B). Given that these pseudotypes can only achieve a single round of infection, this indicates that the observed enhancement in luciferase activity is not attributable to a difference in infectivity, but reflects a CD43-mediated up-regulating effect on HIV-1 gene expression. Finally, we monitored the CD43-dependent effect on virus production by inoculating primary human CD4⫹ T lymphocytes with replication competent virions (i.e. HIV-1NL4-3). Virus production in these cells could not be achieved by measuring levels of p24 because the presence of goat anti-mouse IgG, which were used to multimerize CD43 and/or TCR/CD3, interferes with the p24 enzymatic assay (data not shown). Production of mature virus progeny was then assessed by using the reporter LuSIV cell line. This cell line permits the detection and quantification of single cycle HIV-1 infection because of the Tat-mediated expression of luciferase activity, which correlates with virus infectivity (37). Serial dilutions of the virus-containing culture supernatants were used to avoid saturation of the HIV-1-mediated signal. Results from Fig. 9C indicate that CD43 and TCR/CD3 co-ligation results in an enhancement of virus production, as estimated by luciferase activity, when compared with antibody-mediated engagement of CD43 or TCR/CD3 alone. These findings represent additional evidence of the biological significance of CD43 for the life cycle of HIV-1. DISCUSSION HIV-1 replication is controlled by many different external stimuli such as cytokines and antigens. Indeed, several agents known to induce T-lymphocyte activation have been found to stimulate HIV-1 transcription and replication. T-cell activation requires both antigen receptor-mediated biochemical events and signals provided by some specific co-stimulatory molecules (e.g. CD28). However, little is known about the implication of co-stimulating molecules other than CD28 with respect to activation of HIV-1 gene expression. In this report we show for the first time that one of these co-stimulating molecules, CD43, is a potent co-activator of the HIV-1 LTR, and can lower the threshold of signaling through the TCR䡠CD3 complex necessary to achieve activation of viral replication. Our transient transfection experiments demonstrate that CD43 acts as a very potent co-stimulatory molecule that strongly potentiates TCR/CD3-induced HIV-1 LTR activation. These results are consistent with previous reports describing an enhancement of antigen-specific activation of T-cells by CD43 (14, 65) as well as a potentiation of proliferation and IL-2 secretion induced by CD3 triggering (13, 66). CD43 acts independently from CD28 because their co-stimulating effects are 28722 TCR/CD43 Co-stimulation of HIV-1 LTR additive, suggesting that the two receptors use different signal transduction pathways. Indeed, CD43 is a potent co-activator in murine intestinal intraepithelial lymphocytes, which are largely devoid of CD28 (66), and in T-lymphocytes from CD28deficient mice (16). Hence, CD43 can be envisaged as a functionally important co-stimulating molecule in T-cells. We did not observe any positive effect on HIV-1 transcriptional activity following engagement of CD43 alone, which was in line with the previous observations that reported the necessity of TCR/CD3 triggering for a CD43-mediated stimulation in T-cells. However, Santana and colleagues (22) reported an induction of IL-2 secretion in peripheral blood T-cells using MEM-59, whereas both CD69 and CD40L were induced following treatment with either L10 or MEM-59. The IL-2 promoter is predominantly activated by NFAT and activator protein-1, two transcription factors known to also activate the regulatory domain of HIV-1. Hence, signals that activate the IL-2 promoter should also activate HIV-1 LTR. This discrepancy could be related to the fact that in this study they used peripheral blood T-cells that were probably contaminated by other populations such as monocytes, which may have provided the necessary activating signal. Indeed, the CD43-induced proliferation of human T-cells was shown to be dependent on the presence of monocytes (12). Our results indicate that upon CD43 cross-linking, very little anti-CD3 was necessary to potently activate HIV-1 transcription (Fig. 1D). At the concentrations used here, the anti-CD3 does not display any stimulating capacity by itself, suggesting that CD43 could influence the signaling threshold in T-cells. Moreover, when CD43 was multimerized using the L10 antibody, we did not observe a dose-dependent transcriptional increase in relation to anti-CD3. This observation suggests that when triggered by the L10 antibody, CD43 co-stimulates via its own transduction pathway rather than by enhancing the CD3induced signaling. The situation was different when CD43 was engaged with the MEM-59 antibody because a dose dependence on anti-CD3 antibody was observed. These observations were supported by calcium mobilization studies. Indeed, when using the L10 antibody, there was a synergy between signal transduction pathways that were engaged following cross-linking of both CD43 and CD3 culminating in an augmented Ca2⫹ response (Fig. 8). On the contrary, no such enhancement in calcium mobilization was observed when CD43 was crosslinked by the MEM-59 antibody, indicating that CD43 engagement by MEM-59 and TCR/CD3 triggering share some common calcium-regulated effector(s). These findings are in agreement with a previous study (12) showing that the TCR/CD3 negative Jurkat-derived cell line J.TR3-T3.5 exhibits defective signaling upon CD43 cross-linking by MEM-59, suggesting that this specific anti-CD43 antibody acts via the TCR/CD3 transduction pathway. Moreover, a HPB-ALL-derived cell line severely defective in TCR/CD3 surface expression displays normal L10induced CD43 signaling compared with the parental cell line (18). Thus, the engagement of cell surface CD43 by distinct antibodies that are specific for different epitopes initiates signal transduction events through different pathways. Considering that numerous ligands have been proposed for CD43, it is possible that different sets of genes will be modulated depending on the CD43 epitope that is being recognized by a given ligand. Transient transfection experiments (Figs. 4 and 5) and DNA mobility shift assays (Fig. 6) indicate that the TCR/CD3- and CD43-induced activation of HIV-1 LTR is mediated primarily via NF-␬B and to a smaller extent through NFAT. CD43 engagement alone could not induce any NF-␬B or NFAT binding activity, but could cooperate with a suboptimal CD3 cross- linking to induce translocation of both transcription factors. Similar observations were made when the effect of CD43 crosslinking by L10 and MEM-59 on the distal NFAT site of the IL-2 promoter was tested (67). In that study, simultaneous crosslinking of CD43 by L10 and MEM-59 was sufficient to induce NFAT translocation, suggesting an additive effect of signals generated through each epitope. This observation confirms our hypothesis that CD43 engagement through different epitopes initiates signal transduction events through different pathways. Our results raise the issue of the precise contribution of each of the CD43 and TCR/CD3 signaling pathways in HIV-1 LTR activation. The downstream effectors of the TCR/CD3 signaling cascade p56lck, SLP-76, and p36lat were found to be crucial for TCR/CD3- and CD43-mediated induction of LTR gene expression (Fig. 7), thus suggesting that the activating signal was transduced mainly via the TCR䡠CD3 complex. However, these molecules could as well participate to the CD43-dependent signaling pathway. For example, ligation of CD43 has been reported to generate an interaction between CD43 and p56lck (12, 21), leading to the tyrosine phosphorylation of Shc and the guanosine exchange factor Vav (20). SLP-76 has to be included in this pathway because of its known interaction with Vav. Also, CD43 is functionally coupled to the phospholipase C/phosphoinositides signaling pathway, most likely via the adaptor molecule p36lat, in a CD3-independent manner (18). A working model can then be proposed in which CD43 ligation would induce its association with p56lck and a phosphorylation of this signal transducer, leading to the recruitment of SLP-76 and p36lat, possibly via ZAP-70, activation of phospholipase C␥, and ultimately to a raise in intracellular calcium via the inositide triphosphates and the activation of the mitogen-activated protein kinase pathway via protein kinase C. This possible signaling pathway could be activated upon CD43 ligation by the L10 antibody, whereas ligation by the MEM-59 antibody could increase the TCR/CD3-mediated signaling pathway by a mechanism possibly involving a large complex including CD3 and CD43 (12). The protein-tyrosine kinase p59fyn could also play a role in the CD43-mediated activation because it was found to be associated with CD43 and is phosphorylated upon CD43 ligation (12, 21). This protein kinase could be involved in events leading to the noticed induction of NF-␬B, because it has been shown that overexpression of p59fyn in T cell lines could stimulate HIV-1 LTR activity by NF-␬B-like DNA-binding proteins (68). Further studies are needed to identify the various signal transducers participating to the CD43-mediated signaling cascade. A supplementary role for CD43 in its co-stimulating activity could be in remodeling T-cell morphology. Recently, plasma membrane compartmentalization has been shown to take place following occupancy of the TCR䡠CD3 complex (reviewed in Refs. 69 –71). TCR engagement promotes the integration of components of the TCR/CD3 signaling machinery, including ZAP-70, p36lat, and Vav, into lipid microdomains also called rafts, and the disruption of these microdomains attenuates TCR/CD3-dependent signal transduction events (71). Co-stimulatory molecules, with the exception of CD28, are also present in lipid rafts and it has been proposed that they exert their co-stimulatory effects by contributing to an enhanced association of TCR/CD3 with such raft domains (72). CD43 interacts with the actinbinding proteins moesin and ezrin via its cytoplasmic domain (73, 74). Interestingly, stimulation of T-lymphocytes with antiCD43 antibodies increases this association and induces T-cell polarization as well as the redistribution of CD43 to the uropod (73). Moreover, CD43 seems to be excluded from the antigenic synapse formed between T-cells and dendritic cells (75–79). In TCR/CD43 Co-stimulation of HIV-1 LTR contrast, lipid microdomain clustering in T-cell induces a redistribution of receptors and adhesion molecules leading to a colocalization of CD43 and the TCR in a new microdomain (80). Also, in immature hematopoietic cells, CD43 cross-linking induces the formation of a long-lived cap and an increase in tyrosine phosphorylation through Syk and Lyn tyrosine kinases at the capping site. Interestingly, CD44, which demonstrates a co-stimulatory function very similar to that of CD43 (81), was shown to induce membrane reorganization including the recruitment of CD44 itself and the associated tyrosine kinase p56lck and p59fyn into lipid rafts (82). Because CD43 also interacts with these two tyrosine kinases (12, 21), it is tempting to speculate a similar scenario for CD43 stimulation. Experiments are now being conducted to shed light on this possibility. We have shown here that CD43 functions as a potent costimulatory molecule for TCR/CD3-dependent induction of the HIV-1 LTR-driven transcription, which leads to an increased production of infectious viral particles. This co-stimulatory potential was observed both in the absence and presence of Tat, suggesting that CD43 could play a role in the early phase of the infection, to initiate viral transcription before Tat is produced, as well as in late stages, to enhance virion production. However, it should be noted that the involvement of CD43-mediated biochemical events in HIV-1 transcriptional activity once Tat is also present is most likely minimal. Indeed, the significant Tat-dependent enhancement in HIV-1 LTR activity (i.e. 150fold increase) was only modestly augmented following CD43 and TCR/CD3 co-engagement (i.e. a further 6-fold increase). It can thus be proposed that under in vivo conditions, the costimulating activity of CD43 will primarily have an effect on integrated viral DNA in the absence of Tat. Activation of virus transcription in HIV-1-infected cells can also be achieved via virus-encoded Tat protein that is secreted from already infected cells. Such soluble Tat can activate other cells in trans that are carrying proviral DNA (83, 84). Furthermore, it has been hypothesized that mature HIV-1 particles can harbor TAR-associated Tat molecules (85), which could also directly transactivate proviral DNA. Co-stimulatory molecules such as CD43 can become crucial when the TCR/CD3 signaling pathway is impaired by interaction of the viral gp120 molecule with CD4 (67). Signaling via the CD28 receptor is able to induce HIV-1 replication even in the absence of TCR/CD3 stimulation (5, 6). Because we demonstrate that CD43 co-stimulation needs only a minimal TCR/ CD3 engagement, this molecule could modulate HIV-1 gene expression either in cooperation with CD28 or in CD28-negative cells. Besides, we have recently provided evidence indicating that the more productive HIV-1 infection of T-cells bearing the CD45-RO molecule as compared with CD45-RABC expressing cells is because of a greater activation of the LTR by the NFAT transcription factor (53). Interestingly, memory T-lymphocytes that bear the RO isoform of CD45 display a higher CD43 expression than naive T-cells and this high level of CD43 appears to be involved in the inhibition of apoptosis (26). Hence, it will be interesting to compare the CD43 co-stimulating potential on HIV-1 LTR activity in CD45-RO versus CD45RABC cells. However, for a more complete understanding of the physiological role of CD43 in T-cell development and HIV-1 pathogenesis, the identification of the ligand(s) responsible for its co-stimulatory potential is warranted. Acknowledgments—We thank A. Weiss for providing J14-V-29 and J14-76-11 cells and the pCDNA3.1 LAT expression vector; R. Lewis for CJ, CJ 5.13, and CJ 1.1 cell lines; N. Rice for antibodies against NFAT1, p50 and p65 subunits; J. A. Ledbetter for the 9.3 antibody; and V. Horejski for the MEM-59 antibody. We are indebted to C. Couture for pEFneo and pEFneo LCK-WT; G. Crabtree for pNFAT-LUC; A. Weiss for pCDNA3.1 LAT; K. Calame for pLTR-LUC and pm␬BLTR-LUC; 28723 W. C. Greene for p␬B-TATA-LUC and pCMV-I␬B␣ S32A36A; and N. R. Landau for pNL4-3-LUC-E-R⫹. The JCAM1.6 and JCAM2 cell lines were provided by the American Type Culture Collection. We are grateful to Dr. Maurice Dufour for technical assistance in flow cytometry studies. REFERENCES 1. Nabel, G. J., and Baltimore, D. (1987) Nature 326, 711–713 2. Kinoshita, S., Su, L., Amano, M., Timmerman, L. A., Kaneshima, H., and Nolan, G. P. (1997) Immunity 6, 235–244 3. Tong-Starksen, S. E., Luciw, P. A., and Peterlin, M. B. (1989) J. Immunol. 142, 702–707 4. Copeland, K. F. T., Hendrikx, P. J., Haaksma, A. G. M., Fiering, S., Van Lier, R., Goudsmit, J., and Heeney, J. L. (1995) Virology 209, 633– 636 5. Gruters, R. A., Otto, S. A., Al, B. J., Verhoeven, A. J., Verweij, C. L., Van, L. R., and Miedema, F. (1991) Eur. J. Immunol. 21, 167–172 6. Asjo¨ , B., Cefai, D., Debre´ , P., Dudoit, Y., and Autran, B. (1993) J. Virol. 67, 4395– 4398 7. Jones, A. T., Federsppiel, B., Ellies, L. G., Williams, M. J., Burgener, R., Duronio, V., Smith, C. A., Takei, F., and Ziltener, H. J. (1994) J. Immunol. 153, 3426 –3439 8. Rosenstein, Y., Park, J. K., Hahn, W. C., Rosen, F. S., Bierer, B. E., and Burakoff, S. J. (1991) Nature 354, 233–235 9. Perillo, N. L., Pace, K. E., Seilhamer, J. J., and Baum, L. G. (1995) Nature 378, 736 –739 10. Stockl, J., Majdic, O., Kohl, P., Pickl, W. F., Menzel, J. E., and Knapp, W. (1996) J. Exp. Med. 184, 1769 –1779 11. van den Berg, T. K., Nath, D., Ziltener, H. J., Vestweber, D., Fukuda, M., van Die, I., and Crocker, P. R. (2001) J. Immunol. 166, 3637–3640 12. Alvarado, M., Klassen, C., Cerny, J., Horejsi, V., and Schmidt, R. E. (1995) Eur. J. Immunol. 25, 1051–1055 13. Axelsson, B., Youseffi-Etemad, R., Hammarstrom, S., and Perlmann, P. (1988) J. Immunol. 141, 2912–2917 14. Park, J. K., Rosenstein, Y. J., Remold-O’Donnell, E., Bierer, B. E., Rosen, F. S., and Burakoff, S. J. (1991) Nature 706 –709 15. Mentzer, S. J., Remold-O’Donnell, E., Crimmins, M. A., Bierer, B. E., Rosen, F. S., and Burakoff, S. J. (1987) J. Exp. Med. 165, 1383–1392 16. Sperling, A. I., Green, J. M., Mosley, R. L., Smith, P. L., DiPaolo, R. J., Klein, J. R., Bluestone, J. A., and Thompson, C. B. (1995) J. Exp. Med. 182, 139 –146 17. Axelsson, B., and Perlmann, P. (1989) Scand. J. Immunol. 30, 539 –547 18. Silverman, L. B., Wong, R. C., Remold-O’Donnell, E., Vercelli, D., Sancho, J., Terhorst, C., Rosen, F., Geha, R., and Chatila, T. (1989) J. Immunol. 142, 4194 – 4200 19. Wong, R. C., Remold-O’Donnell, E., Vercelli, D., Sancho, J., Terhorst, C., Rosen, F., Geha, R., and Chatila, T. (1990) J. Immunol. 144, 1455–1460 20. Pedraza-Alva, G., Merida, L. B., Burakoff, S. J., and Rosenstein, Y. (1998) J. Biol. Chem. 273, 14218 –14224 21. Pedraza-Alva, G., Merida, L. B., Burakoff, S. J., and Rosenstein, Y. (1996) J. Biol. Chem. 271, 27564 –27568 22. Santana, M. A., Pedraza-Alva, G., Olivares-Zavaleta, N., Madrid-Marina, V., Horejsi, V., Burakoff, S. J., and Rosenstein, Y. (2000) J. Biol. Chem. 275, 31460 –31468 23. Thurman, E. C., Walker, J., Jayaraman, S., Manjunath, N., Ardman, B., and Green, J. M. (1998) Int. Immunol. 10, 691–701 24. Carlow, D. A., Corbel, S. Y., and Ziltener, H. J. (2001) J. Immunol. 166, 256 –261 25. Brown, T. J., Shuford, W. W., Wang, W. C., Nadler, S. G., Bailey, T. S., Marquardt, H., and Mittler, R. S. (1996) J. Biol. Chem. 271, 27686 –27695 26. He, Y. W., and Bevan, M. J. (1999) J. Exp. Med. 190, 1903–1908 27. Giordanengo, V., Limouse, M., Desroys du Roure, L., Cottalorda, J., Doglio, A., Passeron, A., Fuzibet, J. G., and Lefebvre, J. C. (1995) Blood 86, 2302–2311 28. Lefebvre, J. C., Giordanengo, V., Limouse, M., Doglio, A., Cucchiarini, M., Monpoux, F., Mariani, R., and Peyron, J. F. (1994) J. Exp. Med. 180, 1609 –1617 29. Gallego, M. D., Aguado, E., Kindelan, J. M., Pena, J., Santamaria, M., and Molina, I. J. (2001) Aids 15, 477– 481 30. Siekevitz, M., Joseph, S. F., Dokovich, M., Peffer, N., Wong-Staal, F., and Greene, W. C. (1987) Science 238, 1575–1578 31. Gillis, S., and Watson, J. (1980) J. Exp. Med. 152, 1709 –1719 32. Willard-Gallo, K. E., Van de Keere, F., and Kettmann, R. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 6713– 6717 33. Straus, D. B., and Weiss, A. (1992) Cell 70, 585–593 34. Finco, T. S., Kadlecek, T., Zhang, W., Samelson, L. E., and Weiss, A. (1998) Immunity 9, 617– 626 35. Yablonski, D., Kuhne, M. R., Kadlecek, T., and Weiss, A. (1998) Science 281, 413– 416 36. Fanger, C. M., Hoth, M., Crabtree, G. R., and Lewis, R. S. (1995) J. Cell Biol. 131, 655– 667 37. Roos, J. W., Maughan, M. F., Liao, Z., Hildreth, J. E., and Clements, J. E. (2000) Virology 273, 307–315 38. Henderson, A. J., Zou, X., and Calame, K. L. (1995) J. Virol. 69, 5337–5344 39. Schwartz, O., Virelizier, J.-L., Montagnier, L., and Hazan, U. (1990) Gene (Amst.) 88, 197–205 40. Sun, S.-C., Elwood, J., and Greene, W. C. (1996) Mol. Cell. Biol. 16, 1058 –1065 41. Adachi, A., Gendelman, H. E., Koenig, S., Folks, T., Willey, R., Rabson, A., and Martin, M. A. (1986) J. Virol. 59, 284 –291 42. Chang, L. J., Urlacher, V., Iwakuma, T., Cui, Y., and Zucali, J. (1999) Gene Ther. 6, 715–728 43. Timmerman, L. A., Clipstone, N. A., Ho, S. N., Northrop, J. P., and Crabtree, G. R. (1996) Nature 383, 837– 840 44. Couture, C., Baier, G., Oetken, C., Williams, S., Telford, D., Marie-Cardine, A., 28724 TCR/CD43 Co-stimulation of HIV-1 LTR Baier-Bitterlich, G., Fisher, S., Burn, P., Altman, A., and Mustelin, T. (1994) Mol. Cell. Biol. 14, 5249 –5258 45. Yee, J. K., Friedmann, T., and Burns, J. C. (1994) Methods Cell Biol. 43, 99 –112 46. Martin, P. J., Ledbetter, J. A., Morishita, Y., June, C. H., Beatty, P. G., and Hansen, J. A. (1986) J. Immunol. 136, 3282–3287 47. Stefanova, I., Hilgert, I., Kristofova, H., Brown, R., Low, M. G., and Horejsi, V. (1989) Mol. Immunol. 26, 153–161 48. Lyakh, L., Ghosh, P., and Rice, N. R. (1997) Mol. Cell. Biol. 17, 2475–2484 49. Barbeau, B., Bernier, R., Dumais, N., Briand, G., Olivier, M., Faure, R., Posner, B. I., and Tremblay, M. J. (1997) J. Biol. Chem. 272, 12968 –12977 50. Cantin, R., Fortin, J.-F., and Tremblay, M. (1996) Virology 218, 372–381 51. Fortin, J. F., Cantin, R., Lamontagne, G., and Tremblay, M. (1997) J. Virol. 71, 3588 –3596 52. Bounou, S., Leclerc, J. E., and Tremblay, M. J. (2002) J. Virol. 76, 1004 –1014 53. Robichaud, G. A., Barbeau, B., Fortin, J. F., Rothstein, D. M., and Tremblay, M. J. (2002) J. Biol. Chem. 277, 23733–23741 54. Finco, T., Beg, A., and Baldwin, A. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 11884 –11888 55. Bassuk, A. G., Anandappa, R. T., and Leiden, J. M. (1997) J. Virol. 71, 3563–3573 56. Cron, R. Q., Bartz, S. R., Clausell, A., Bort, S. J., Klebanoff, S. J., and Lewis, D. B. (2000) Clin. Immunol. 94, 179 –191 57. Flanagan, W. M., Corthesy, B., Bram, R. J., and Crabtree, G. R. (1991) Nature 352, 803– 807 58. Liu, J., Farmer, J. D. J., Lane, W. S., Friedman, J., Weissman, I., and Schreiber, S. L. (1991) Cell 66, 807– 815 59. Barbeau, B., Robichaud, G. A., Fortin, J.-F., and Tremblay, M. J. (2001) J. Immunol. 167, 2700 –2713 60. Barber, E. K., Dasgupta, J. D., Schlossman, S. F., Trevillyan, J. M., and Rudd, C. E. (1989) Proc. Natl. Acad. Sci. U. S. A. 86, 3277–3281 61. Neumeister, E. N., Zhu, Y., Richard, S., Terhorst, C., Chan, A. C., and Shaw, A. S. (1995) Mol. Cell. Biol. 15, 3171–3178 62. Zhang, W., Sloan-Lancaster, J., Kitchen, J., Trible, R. P., and Samelson, L. E. (1998) Cell 92, 83–92 63. Wardenburg, J. B., Fu, C., Jackman, J. K., Flotow, H., Wilkinson, S. E., Williams, D. H., Johnson, R., Kong, G., Chan, A. C., and Findell, P. R. (1996) J. Biol. Chem. 271, 19641–19644 64. Putney, J. W., Jr., and Bird, G. S. (1993) Cell 75, 199 –201 65. Hamad, M., Mosley, R. L., Wang, J., and Klein, J. R. (1996) Dev. Comp. Immunol. 20, 77– 82 66. Bagriacik, E. U., Tang, M., Wang, H. C., and Klein, J. R. (2001) Immunol. Cell Biol. 79, 303–307 67. Cefai, D., Debre, P., Kaczorek, M., Idziorek, T., Autran, B., and Bismuth, G. (1990) J. Clin. Invest. 86, 2117–2124 68. Hohashi, N., Hayashi, T., Fusaki, N., Takeuchi, M., Higurashi, M., Okamoto, T., Semba, K., and Yamamoto, T. (1995) Int. Immunol. 7, 1851–1859 69. Cherukuri, A., Dykstra, M., and Pierce, S. K. (2001) Immunity 14, 657– 660 70. Janes, P. W., Ley, S. C., Magee, A. I., and Kabouridis, P. S. (2000) Semin. Immunol. 12, 23–34 71. Viola, A. (2001) Trends Immunol. 22, 322–327 72. Yashiro-Ohtani, Y., Zhou, X. Y., Toyo-Oka, K., Tai, X. G., Park, C. S., Hamaoka, T., Abe, R., Miyake, K., and Fujiwara, H. (2000) J. Immunol. 164, 1251–1259 73. Serrador, J. M., Nieto, M., Alonso-Lebrero, J. L., del Pozo, M. A., Calvo, J., Furthmayr, H., Schwartz-Albiez, R., Lozano, F., Gonzalez-Amaro, R., Sanchez-Mateos, P., and Sanchez-Madrid, F. (1998) Blood 91, 4632– 4644 74. Yonemura, S., Hirao, M., Doi, Y., Takahashi, N., Kondo, T., and Tsukita, S. (1998) J. Cell Biol. 140, 885– 895 75. Revy, P., Sospedra, M., Barbour, B., and Trautmann, A. (2001) Nat. Immunol. 2, 925–931 76. Savage, N. D., Kimzey, S. L., Bromley, S. K., Johnson, K. G., Dustin, M. L., and Green, J. M. (2002) J. Immunol. 168, 3740 –3746 77. Gubina, E., Chen, T., Zhang, L., Lizzio, E. F., and Kozlowski, S. (2002) Blood 99, 2518 –2525 78. Allenspach, E. J., Cullinan, P., Tong, J., Tang, Q., Tesciuba, A. G., Cannon, J. L., Takahashi, S. M., Morgan, R., Burkhardt, J. K., and Sperling, A. I. (2001) Immunity 15, 739 –750 79. Delon, J., Kaibuchi, K., and Germain, R. N. (2001) Immunity 15, 691–701 80. Mitchell, J. S., Kanca, O., and McIntyre, B. W. (2002) J. Immunol. 168, 2737–2744 81. Foger, N., Marhaba, R., and Zoller, M. (2000) Eur. J. Immunol. 30, 2888 –2899 82. Foger, N., Marhaba, R., and Zoller, M. (2001) J. Cell Sci. 114, 1169 –1178 83. Albini, A., Ferrini, S., Benelli, R., Sforzini, S., Giunciuglio, D., Aluigi, M. G., Proudfoot, A. E., Alouani, S., Wells, T. N., Mariani, G., Rabin, R. L., Farber, J. M., and Noonan, D. M. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 13153–13158 84. Trinh, D. P., Brown, K. M., and Jeang, K. T. (1999) Biochem. Biophys. Res. Commun. 256, 299 –306 85. Huang, L. M., Joshi, A., Willey, R., Orenstein, J., and Jeang, K. T. (1994) EMBO J. 13, 2886 –2896